T. Rowe Price Associates’s Cantel Medical Corporation CMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-526,211
| Closed | -$42M | – | 2975 |
|
|
2021
Q1 | $42M | Sell |
526,211
-15,991
| -3% | -$1.25M | ﹤0.01% | 1062 |
|
|
2020
Q4 | $42.8M | Sell |
542,202
-3,465
| -0.6% | -$203K | ﹤0.01% | 1012 |
|
|
2020
Q3 | $24M | Buy |
545,667
+12,517
| +2% | +$617K | ﹤0.01% | 1105 |
|
|
2020
Q2 | $23.6M | Sell |
533,150
-2,415
| -0.5% | -$90.1K | ﹤0.01% | 1102 |
|
|
2020
Q1 | $19.2M | Sell |
535,565
-57,397
| -10% | -$3.26M | ﹤0.01% | 1086 |
|
|
2019
Q4 | $42M | Sell |
592,962
-2,473
| -0.4% | -$179K | 0.01% | 973 |
|
|
2019
Q3 | $44.5M | Sell |
595,435
-3,288
| -0.5% | -$279K | 0.01% | 913 |
|
|
2019
Q2 | $48.3M | Sell |
598,723
-2,901
| -0.5% | -$204K | 0.01% | 909 |
|
|
2019
Q1 | $40.2M | Sell |
601,624
-3,672
| -0.6% | -$278K | 0.01% | 957 |
|
|
2018
Q4 | $45.1M | Buy |
605,296
+7,304
| +1% | +$603K | 0.01% | 868 |
|
|
2018
Q3 | $55.1M | Buy |
597,992
+40,260
| +7% | +$3.83M | 0.01% | 879 |
|
|
2018
Q2 | $54.9M | Buy |
557,732
+117,643
| +27% | +$13.2M | 0.01% | 862 |
|
|
2018
Q1 | $49M | Buy |
440,089
+28,172
| +7% | +$3.16M | 0.01% | 881 |
|
|
2017
Q4 | $42.4M | Buy |
411,917
+9,240
| +2% | +$920K | 0.01% | 922 |
|
|
2017
Q3 | $37.9M | Buy |
402,677
+19,378
| +5% | +$1.53M | 0.01% | 957 |
|
|
2017
Q2 | $29.9M | Buy |
383,299
+15,570
| +4% | +$1.17M | 0.01% | 1022 |
|
|
2017
Q1 | $29.5M | Buy |
367,729
+41,030
| +13% | +$3.26M | 0.01% | 1004 |
|
|
2016
Q4 | $25.7M | Buy |
326,699
+18,900
| +6% | +$1.47M | 0.01% | 1054 |
|
|
2016
Q3 | $24M | Buy |
307,799
+31,687
| +11% | +$2.3M | ﹤0.01% | 1069 |
|
|
2016
Q2 | $19M | Buy |
276,112
+17,922
| +7% | +$1.24M | ﹤0.01% | 1118 |
|
|
2016
Q1 | $18.4M | Buy |
258,190
+36,400
| +16% | +$2.28M | ﹤0.01% | 1111 |
|
|
2015
Q4 | $13.8M | Buy |
221,790
+212,190
| +2,210% | +$12.9M | ﹤0.01% | 1203 |
|
|
2015
Q3 | $544K | Hold |
9,600
| – | – | ﹤0.01% | 1914 |
|
|
2015
Q2 | $515K | Hold |
9,600
| – | – | ﹤0.01% | 1984 |
|
|
2015
Q1 | $456K | Buy |
9,600
+3,200
| +50% | +$142K | ﹤0.01% | 2018 |
|
|
2014
Q4 | $277K | Sell |
6,400
-1,500
| -19% | -$61.3K | ﹤0.01% | 2211 |
|
|
2014
Q3 | $272K | Hold |
7,900
| – | – | ﹤0.01% | 2189 |
|
|
2014
Q2 | $289K | Hold |
7,900
| – | – | ﹤0.01% | 2200 |
|
|
2014
Q1 | $266K | Buy |
7,900
+400
| +5% | +$13.2K | ﹤0.01% | 2211 |
|
|
2013
Q4 | $254K | Hold |
7,500
| – | – | ﹤0.01% | 2223 |
|
|
2013
Q3 | $239K | Buy |
+7,500
| New | +$199K | ﹤0.01% | 2201 |
|
T. Rowe Price Associates's CMD Position: Q2 2021 in Review
T. Rowe Price Associates sold out of Cantel Medical Corporation (CMD) in Q2 2021, closing a stake of 526,211 shares — an estimated $42M sold.
T. Rowe Price Associates first reported a position in CMD in Q3 2013 and held it in 31 quarters. The position peaked at $55.1M in Q3 2018. 0 funds tracked by Wall St. Rank hold CMD as of Q2 2021.
- T. Rowe Price Associates reported no remaining Cantel Medical Corporation position as of Q2 2021 after selling out during the quarter.
- T. Rowe Price Associates sold 526,211 Cantel Medical Corporation shares in Q2 2021, an estimated $42M.
- T. Rowe Price Associates first reported a position in Cantel Medical Corporation in Q3 2013 and held it in 31 quarters.
- T. Rowe Price Associates's Cantel Medical Corporation position peaked at $55.1M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Cantel Medical Corporation as of Q2 2021.
Based on T. Rowe Price Associates's 13F filing for Q2 2021, filed 16 Aug 2021.